Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec;5(23):467.
doi: 10.21037/atm.2017.09.32.

Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors

Denira Imamovic  1 , Semir Vranic  1   2   3
Affiliations
Editorial

Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors

Denira Imamovic et al. Ann Transl Med. 2017 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comment on

  • Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.
    Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, Logtenberg MEW, Slagter M, Rozeman EA, Hofland I, Broeks A, Horlings HM, Wessels LFA, Blank CU, Xiao Y, Heck AJR, Borst J, Brummelkamp TR, Schumacher TNM. Mezzadra R, et al. Nature. 2017 Sep 7;549(7670):106-110. doi: 10.1038/nature23669. Epub 2017 Aug 16. Nature. 2017. PMID: 28813410 Free PMC article.
  • CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.
    Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, Lam EYN, Henderson MA, Bell CC, Stolzenburg S, Gilan O, Bloor S, Noori T, Morgens DW, Bassik MC, Neeson PJ, Behren A, Darcy PK, Dawson SJ, Voskoboinik I, Trapani JA, Cebon J, Lehner PJ, Dawson MA. Burr ML, et al. Nature. 2017 Sep 7;549(7670):101-105. doi: 10.1038/nature23643. Epub 2017 Aug 16. Nature. 2017. PMID: 28813417 Free PMC article.

References

    1. Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther 2015;14:847-56. 10.1158/1535-7163.MCT-14-0983 - DOI - PubMed
    1. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409-13. 10.1126/science.aan6733 - DOI - PMC - PubMed
    1. Guan J, Lim KS, Mekhail T, et al. Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers. Arch Pathol Lab Med 2017;141:851-61. 10.5858/arpa.2016-0361-RA - DOI - PubMed
    1. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7. 10.1038/nature14011 - DOI - PMC - PubMed
    1. Boussiotis VA. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med 2016;375:1767-78. 10.1056/NEJMra1514296 - DOI - PMC - PubMed